Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg in the Morning vs Lapaquistat Acetate 100 mg in the Evening vs Lapaquistat Acetate 50 mg Twice Daily vs Placebo in Subjects With Hypercholesterolemia

NCT00865228 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT00865228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00865228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg in the Morning vs Lapaquistat Acetate 100 mg in the Evening vs Lapaquistat Acetate 50 mg Twice Daily vs Placebo in Subjects With Hypercholesterolemia
Lead sponsor
Takeda
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2007
Completion date
November 30, 2007
Enrollment
224 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia